PYPD News and Press, PolyPid Ltd. From 02/09/22

PolyPid Ltd. (PYPD) Q4 2021 Earnings Conference Call February 9, 2022, 08:30 AM ET Company Participants Bob Yedid - Investor Relations Amir Weisberg - Chief Executive Officer Dikla Czaczkes Akselbrad – Executive Vice President and Chief Financial Officer Conference Call Participants Ha...

PolyPid press release (NASDAQ:PYPD): Q4 GAAP EPS of -$0.71 misses by $0.17. As of December 31, 2021, the Company had cash and cash equivalents and deposits in the amount of $32.2 million, compared to $66.6 million at December 31, 2020. PolyPid expects that this cash balance wil...

• FDA A greed to PolyPid Request for the Addition of an Unblinded Interim Analysis in SHIELD I once 750 Patients Co mplete their 30 - day F ollow-up • Recruitment Progressing as Planned with Appr...

PETACH TIKVA, Israel, Jan. 26, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its prop...

Dr. Berger Brings Extensive Expertise in Deep Brain Tumor Treatment The Company Expects to Initiate a Phase 1/2 Clinical Trial of OncoPLEX for Brain Tumors by the end of 2022 PETAH TIKVA, Israel, Jan. 04, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ) ( ...

PETAH TIKVA, Israel, Jan. 03, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ) (“PolyPid” or the “Company”), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its propri...

PETAH TIKVA, Israel, Nov. 18, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ) (“PolyPid” or the “Company”), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics to improve surgi...

PETAH TIKVA, Israel, Nov. 16, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLE...

PolyPid Ltd. (PYPD) Q3 2021 Earnings Conference Call November 10, 2021 8:30 AM ET Company Participants Amir Weisberg – Chief Executive Officer Dikla Czaczkes Akselbrad – Executive Vice President and Chief Financial Officer Conference Call Participants Gary Mattan – BMO Ca...

Recruitment Progressing as Planned with Approximately 480 Patients Enrolled in Phase 3 SHIELD I Trial of D-PLEX 100 in Abdominal Surgery Following FDA Agreement that a Single Pivotal Phase 3 Study is Sufficient for Potential Approval of D-PLEX 100 for the Pre...